<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124248">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01738373</url>
  </required_header>
  <id_info>
    <org_study_id>MOZ22510</org_study_id>
    <nct_id>NCT01738373</nct_id>
  </id_info>
  <brief_title>Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation</brief_title>
  <official_title>Investigator Centers Will Be All French Hematology Centers Performing Autologous Transplantation and Prescribing Mozobil in Hematopoietic Stem Cell Mobilization Willing to Participate In This Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genzyme, a Sanofi Company</source>
  <oversight_info>
    <authority>France: Direction Générale de la Santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this registry is to provide information, in day-to-day practice, on Plerixafor
      prescription modalities in France, over a 13-month period in order to address the health
      authorities' request.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>The characteristics of the patients who received treatment</measure>
    <time_frame>13 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Dosage of treatment</measure>
    <time_frame>13 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of CD34+ cells collected following treatment</measure>
    <time_frame>13 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with the existence of one or more predictive factors of poor mobilisation</measure>
    <time_frame>13 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of treatment</measure>
    <time_frame>13 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Associated treatments</measure>
    <time_frame>13 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">262</enrollment>
  <condition>Bone Marrow / Autologous Transplants</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plerixafor</intervention_name>
    <description>Plerixafor will be prescribed independently by the physician, according to usual practice.</description>
    <other_name>Mozobil®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The selection of the registry's participants will be based on an exhaustive request of all
        apheresis centers distributed in the French territory.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients treated with Plerixafor for autologous transplantation between November 2011
             and November 2012

          -  Patients who have been informed and who have given their written consent for the
             access to their medical file

        Exclusion Criteria:

          -  Patients already included in a Plerixafor ongoing clinical trial.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 19, 2013</lastchanged_date>
  <firstreceived_date>November 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>autologous stem cell transplantation</keyword>
  <keyword>lymphoma</keyword>
  <keyword>multiple myeloma</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>JM 3100</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
